Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avalo Therapeutics Inc AVTX

Healthcare Biotechnology
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1ß mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1ß (IL-1ß... see more

Recent & Breaking News (NDAQ:AVTX)

Cerecor Announces Acquisition of TARP-γ8-AMPA Receptor Antagonist (CERC-611) from Lilly

Business Wire September 26, 2016

Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder

Business Wire September 21, 2016

Cerecor Enters Into a $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

Business Wire September 12, 2016

Cerecor Announces Last Patient Enrolled in Phase 2 Clinical Trial with CERC-501 for Smoking Cessation

Business Wire September 6, 2016

Cerecor to Present at 23rd Annual NewsMakers in the Biotech Industry Conference in New York City, September 9, 2016

Business Wire September 1, 2016

Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers

Business Wire August 29, 2016

Cerecor to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016

Business Wire August 22, 2016

Cerecor Inc. Reports Second Quarter 2016 Financial Results

Business Wire August 15, 2016

Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder

Business Wire July 25, 2016

Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health

Business Wire July 20, 2016